End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4,45,000.00 KRW | +1.37% |
|
+6.71% | +43.78% |
27/03 | Merck plans to launch US subcutaneous version of Keytruda on October 1 | RE |
17/03 | AstraZeneca: exclusive licensing agreement with Alteogen | CF |
Capitalization | 23,78100Cr 1.72TCr 1.47TCr 1.37TCr 1.28TCr 2.36TCr 1,48000Cr 2.62TCr 17TCr 6.27TCr 69TCr 6.46TCr 6.32TCr 2,53900Cr | P/E ratio 2025 * |
326x | P/E ratio 2026 * | 48.2x |
---|---|---|---|---|---|
Enterprise value | 2.36TCr 1.71Cr 1.46Cr 1.36Cr 1.27Cr 2.34Cr 147.05Cr 2.61Cr 16Cr 6.23Cr 69Cr 6.41Cr 6.28Cr 252.28Cr | EV / Sales 2025 * |
115x | EV / Sales 2026 * | 42.5x |
Free-Float |
72.75% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
More press releases
1 day | +1.37% | ||
1 week | +6.71% | ||
Current month | +19.62% | ||
1 month | +15.43% | ||
3 months | +14.99% | ||
6 months | +44.72% | ||
Current year | +43.78% |
1 week | 4,13,000 | ![]() | 4,53,000 |
1 month | 3,71,000 | ![]() | 4,53,000 |
Current year | 2,98,000 | ![]() | 4,59,500 |
1 year | 2,42,000 | ![]() | 4,59,500 |
3 years | 27,875 | ![]() | 4,59,500 |
5 years | 27,875 | ![]() | 4,59,500 |
10 years | 3,590.28 | ![]() | 4,59,500 |
Manager | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 70 | 13/05/2008 |
Byung-Kyu Lee
AUD | Comptroller/Controller/Auditor | 59 | 29/03/2021 |
Gyu-Wan Kim
PRN | Corporate Officer/Principal | 59 | - |
Director | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CHM | Chairman | 70 | 13/05/2008 |
In-Young Go
BRD | Director/Board Member | 69 | 29/03/2021 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+1.37% | +6.71% | +63.30% | +724.07% | 1.72TCr | ||
+3.75% | +1.92% | -18.76% | -16.24% | 7.67TCr | ||
+0.50% | +6.04% | -48.13% | -4.72% | 6.03TCr | ||
-1.42% | +4.20% | +26.61% | +26.30% | 5.37TCr | ||
+0.03% | +1.47% | +19.99% | +106.71% | 3.83TCr | ||
-0.82% | +2.29% | -42.14% | -37.88% | 1.95TCr | ||
+3.72% | +3.22% | +117.39% | +130.66% | 1.79TCr | ||
-0.04% | -.--% | +68.78% | +135.69% | 1.4TCr | ||
+2.03% | +4.03% | +9.93% | -12.12% | 1.35TCr | ||
-2.29% | +9.93% | -72.94% | -79.45% | 1.27TCr | ||
Average | +0.58% | +2.73% | +12.40% | +97.30% | 3.24TCr | |
Weighted average by Cap. | +0.92% | +2.39% | +1.20% | +57.91% |
2025 * | 2026 * | |
---|---|---|
Net sales | 21TCr 15Cr 13Cr 12Cr 11Cr 20Cr 1.28TCr 23Cr 142.75Cr 54Cr 597.99Cr 56Cr 55Cr 2.19TCr | 54TCr 39Cr 34Cr 31Cr 29Cr 54Cr 3.39TCr 60Cr 378.23Cr 143.38Cr 1.58TCr 147.69Cr 144.66Cr 5.81TCr |
Net income | 7.3TCr 5.28Cr 4.52Cr 4.21Cr 3.93Cr 7.23Cr 454.37Cr 8.06Cr 51Cr 19Cr 212.58Cr 20Cr 19Cr 779.51Cr | 49TCr 36Cr 31Cr 29Cr 27Cr 49Cr 3.08TCr 55Cr 343.75Cr 130.31Cr 1.44TCr 134.23Cr 131.47Cr 5.28TCr |
Net Debt | -16TCr -11Cr -9.62Cr -8.95Cr -8.36Cr -15Cr -966.31Cr -17Cr -107.92Cr -41Cr -452.09Cr -42Cr -41Cr -1.66TCr | -65TCr -47Cr -40Cr -38Cr -35Cr -64Cr -4.05TCr -72Cr -452.2Cr -171.42Cr -1.89TCr -176.57Cr -172.94Cr -6.95TCr |
More financial data
* Estimated data
Employees
155
Sector
Pharmaceuticals
Calendar
Date | Price | Change | Volume |
---|---|---|---|
14/25/14 | 4,45,000.00 ₩ | +1.37% | 2,67,180 |
11/25/11 | 4,39,000.00 ₩ | -2.23% | 3,52,929 |
10/25/10 | 4,49,000.00 ₩ | +6.02% | 9,18,273 |
09/25/09 | 4,23,500.00 ₩ | +1.07% | 3,73,649 |
08/25/08 | 4,19,000.00 ₩ | +0.48% | 4,00,000 |
End-of-day quote Korea S.E., July 14, 2025
More quotesSell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
4,45,000.00KRW
Average target price
5,65,000.00KRW
Spread / Average Target
+26.97%
Annual profits - Rate of surprise
- Stock Market
- Equities
- A196170 Stock
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition